Elsevier purchases oncology portfolio

Elsevier purchased Cancer Information Group's (CIG) oncology journal portfolio for an undisclosed sum. The acquisition, which includes six titles, will leave the journals' editors and editorial boards unchanged; David Allen, formerly CIG's managing editor, is now managing editor at Elsevier.
“The CIG titles are attractive because they provide high-quality peer-reviewed content—which Elsevier will seek to further improve in partnership with the editorial teams—in this dynamic area of research and clinical practice,” said Tom Reller, Elsevier's VP, global corporate relations, in an email. “Oncology is an important growth area for Elsevier, with increasing disease incidence, new therapeutic options for patients, and increasing numbers of papers published each year,” he said.
The titles, which include Clinical Breast Cancer, Clinical Lung Cancer, Clinical Lymphoma Myeloma & Leukemia, Clinical Colorectal Cancer, Clinical Ovarian Cancer and Clinical Genitourinary Cancer, will be available online and in print, with advertising opportunities available in both formats, Reller said.
Glen Campbell, EVP, global medical research, Elsevier, said in a statement that “Authors will benefit from the upcoming release of enhanced online manuscript submission and review systems for the journals, as well as the range of author support tools provided by Elsevier.”
You must be a registered member of MMM to post a comment.

Next Article in Features

Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.

Email Newsletters